Latest Content

In the third part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, points out that from employer-paid premiums to Medicare and Medicaid subsidies, the US system relies on layered financial support to keep coverage within reach—underscoring how few individuals can realistically pay the full cost of care or insurance on their own.

In today’s Pharma Pulse, Novartis calls for a shift from "cost-containment" to structural reform, hospital mergers hit their lowest point in 15 years, and new data warns of "cost shocks" driven by copay accumulators.

The company brings its temperature-controlled Superbox to the US pharma industry, aiming to improve speed, compliance, and resilience in the cold chain process.

In the second part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, describes how rising healthcare and living costs are expanding financial hardship beyond traditional eligibility thresholds, while safety-net resources shrink and demand accelerates.

In today’s Pharma Pulse, President Trump unveils a patient payment plan, the FDA flags a rare seizure risk for several leading flu vaccines, and MJH Life Sciences expands its data-driven reach.

The company’s latest preview report projects a guarded rebound for biopharma, as investor confidence returns and M&A activity accelerates.

In the first part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, explains how mounting financial pressure is forcing patients to ration care, undermining treatment adherence and accelerating downstream clinical and economic risk.

In today’s Pharma Pulse, AbbVie joins TrumpRx, shingles vaccines reveal a longevity boost, and HER2 therapies break new ground in cancer treatment.

The company will participate in the Trump administration’s direct-to-patient drug platform, while committing $100 billion to US R&D and manufacturing.

In today’s Pharma Pulse, Novartis expands its US radioligand footprint, and 15,000 New York City nurses go on strike.

The pharma giant will invest in a 35,000-square-foot RLT manufacturing site in Winter Park, FL as part of its $23 billion US infrastructure expansion.

In the third part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, shares how automatic contract adjustments tied to labor, energy, and inflation—combined with the critical role of supply reliability—allow the company to pass through limited surcharges while maintaining strong client relationships.

In today’s Pharma Pulse, Amazon Pharmacy launches Novo's first oral Wegovy pill with transparent cash pricing, Johnson & Johnson triples down on North Carolina manufacturing, and new clinical data links medical debt to rising eviction risks.